Rx Product News (March 2015)

Pharmacy TimesMarch 2015 Central Nervous System
Volume 81
Issue 3

Read about the new Rx Products featured in March.

Galderma Laboratories, LP

Indication: The FDA has approved Soolantra (ivermectin) Cream, 1%, for the treatment of the inflammatory lesions of rosacea. The recommended dose is a thin layer spread onto the affected area(s) once a day. Patients should avoid their lips and eyes.

Dosage Form: Cream: 1%, available in 30-, 45-, and 60-g tubes

For More Information: www.soolantra.com

VyvanseMarketed by: Shire Plc

Indication: The FDA has approved Vyvanse (lisdexamfetamine dimesylate), a central nervous system stimulant, for the treatment of moderate to severe binge eating disorder in adults. The recommended starting dose for patients with binge eating disorder is 30 mg by mouth every morning; dose titration may occur by 20 mg every week, up to a maximum dose of 70 mg per day. Vyvanse is a Schedule II controlled substance.

Dosage Form: Capsules: 10, 20, 30, 40, 50, 60, and 70 mg

For More Information: www.vyvanse.com

CosentyxMarketed by: Novartis Pharmaceuticals

Indication: The FDA has approved Cosentyx (secukinumab), a human interleukin-17A antagonist, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. The recommended dose is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. A dose of 150 mg may be acceptable for some patients.

Dosage Form: Injection: 150 mg/mL solution in a single-use pen or prefilled syringe, or 150 mg of lyophilized powder in a single-use vial for reconstitution

For More Information: www.cosentyx.com

RytaryMarketed by: Impax Laboratories, Inc

Indication: The FDA has approved Rytary, a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid), for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. The recommended starting dose for levodopa-naive patients is 23.75/95 mg by mouth 3 times per day; this may increase to 36.25/145 mg by mouth 3 times per day on the fourth day of treatment. The maximum recommended daily dose of Rytary is 612.5/2450 mg.

Dosage Form: Extended-release capsules: 23.75/95, 36.25/145, 48.75/195, and 61.25/245 mg

For More Information: www.rytary.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.